Jeil Pharmaceutical

At a glance

Jeil Pharmaceutical filed 16 disclosures in the last 12 months, including 1 5% holder and 1 buyback. The most recent key filing was on Apr 30.

Revenue for 2025 was ₩567B, down 19.5% on 2024. Operating margin was 3.6% against -2.7% a year earlier. Debt was 103% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩277B and operating loss of ₩6.6B.

The 2025 annual report lists 1,011 employees with an average tenure of 7.9 years and average pay of ₩63.8M, #816 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩192.8M each on average. It paid no cash dividend for 2025. 한승수 and related parties held 62.28% at year end.

From the 2025 annual report

Staff: 1,011 (729 men, 282 women), of whom 33 on fixed-term contracts. Total pay for the year: ₩64.5B. Directors and auditors: 8, paid ₩1.5B in total.

No cash dividend was paid for 2025.

Largest shareholder

한승수 holds 3.00%; with 8 related parties the group holds 62.28% of common shares at year end.

Auditor: 이촌회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary